2,5-Dimethoxy-4-cyanoamphetamine (DOCN) is a serotonergic drug of the phenethylamine, amphetamine, and DOx families. It is a DOx derivative with a cyano group (âÂÂCâ¡N) at the 4position of the molecule.
The effects of DOCN in humans and whether it is a psychedelic are unknown.
DON shows much lower affinities for the serotonin 5-HT<sub>2</sub> receptors than other DOx drugs. However, DOCN also showed by far the greatest degree of selectivity for the serotonin 5-HT<sub>2A</sub> receptor over the serotonin 5-HT<sub>2C</sub> receptor (22-fold) of any other assessed DOx drug. Applying this strategy (i.e., cyano substitution) to the 25-NB series resulted in the discovery of 25CN-NBOH, one of the most selective serotonin 5-HT<sub>2A</sub> receptor agonists discovered to date.
Related drugs include DON, 2C-N, DOA, 2C-CN, 25CN-NBOH, and 25CN-NBOMe.
DOCN was first described in the scientific literature by Richard Glennon and colleagues by 1989.
DOCN is a controlled substance in Canada under phenethylamine blanket-ban language.
DOCN is not a controlled substance in the United States as of 2011.